<DOC>
	<DOCNO>NCT02564796</DOCNO>
	<brief_summary>Cyanotic congenital cardiac patient require high hemoglobin concentration ( red blood cell level ) optimal oxygen delivery body . Prophylactic erythropoietin ( EPO ) iron prevent and/or decrease amount blood transfusion need population . We seek investigate EPO iron make clinically significant difference number transfusion give patient morbidity associate .</brief_summary>
	<brief_title>Erythropoietin Prevent Unnecessary Transfusions In Patients With Cyanotic Congenital Heart Disease - A Prospective Control Trial</brief_title>
	<detailed_description>Congenital heart disease occur 1 % live birth . Cyanotic cardiac lesion particular risk significant mortality morbidity reduce ability provide adequate oxygenation body brain . Many expert believe adequate oxygen carry capacity infant ideally hemoglobin level great 13 g/dL . Many patient require blood transfusion prior surgery provide adequate oxygenation . The cause likely multifactorial include normal neonatal physiology , frequent lab draw , co-morbidities . Although rare , morbidity due transfusion devastate population include transmitted infection , transfusion reaction , extra hospitalization , antigen sensitization would complicate heart transplant need . There center United States develop protocol use erythropoietin minimize blood product transfusion surgery , also refer `` bloodless surgery '' . There retrospective study evaluate success protocol , randomize control prospective study investigator study effect erythropoietin effect patient cyanotic heart disease regard transfusion prevention . Congenital cyanotic cardiac patient require high hemoglobin concentration optimal oxygen delivery . Prophylactic erythropoietin prevent and/or decrease amount blood transfusion need prior surgery . The researcher seek investigate erythropoietin make clinically significant difference number transfusion give patient morbidity associate .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Cyanosis</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Inclusion Criteria Newborns le 4 week old diagnosis Gestational age &gt; 34 week Birth weight 2.24kg Cyanotic heart disease surgical shunt catheterization intervention equivalent shunt ( patent ductus arteriosus stent , right ventricular outflow tract stent ) . Baseline hematocrit &lt; 40 % . Completes least 1 injection study 8 week age . Exclusion Criteria Infants diagnose great 4 week age Gestation &lt; 34 week Birth weight &lt; 2.2 kg &gt; 4kg Hematocrit &gt; 40 % Newborns acyanotic heart disease Infants significant comorbidities : Renal failure ( Creatinine &gt; 2 standard deviation age adjust norm ) Hepatic failure ( elevate AST/ALT level &gt; 2 standard deviation age adjust norm Hemolytic disease Hemoglobinopathies ( Sicklecell disease , Thalassemias )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Erythropoetin</keyword>
	<keyword>Cyanotic Heart Disease</keyword>
	<keyword>Transfusion</keyword>
	<keyword>Congenital Heart Disease</keyword>
</DOC>